½ÃÀ庸°í¼­
»óǰÄÚµå
1474900

´Ü¹éÁú Ĩ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Protein Chip Market Size, Share & Trends Analysis Report By Type (Analytical Microarrays, Reverse Phase Protein Microarrays), By Application (Antibody Characterization, Clinical Diagnostics), By End-use, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

´Ü¹éÁú Ĩ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ ´Ü¹éÁú Ĩ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 33¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024-2030³âÀÇ CAGRÀº 6.88%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ ¹è°æ¿¡´Â ´Ü¹éÁúüÇÐ ¿¬±¸ÀÇ Áö¼ÓÀûÀÎ ¹ßÀü, ½Å¾à °³¹ß ¹× ¿¬±¸°³¹ß Áõ°¡, Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀÌ ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ Áß ´Ü¹éÁú Ĩ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀº Àü ¼¼°è ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, COVID-19 ÆÒµ¥¹ÍÀº ¼¼°è º¸°Ç ¹®Á¦¸¦ ÇØ°áÇÏ´Â µ¥ ÀÖÀ¸¸ç, ´Ü¹éÁú Ĩ°ú °°Àº ÷´Ü ±â¼úÀÇ Á߿伺À» Àü¸é¿¡ ºÎ°¢½ÃÄ×½À´Ï´Ù. ÀÌ´Â ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÅõÀÚ¸¦ È®´ëÇÏ¿© Áúº´ ¿¬±¸, Áø´Ü ¹× ¸ÂÃãÇü ÀÇ·á ºÐ¾ß¿¡¼­ ´Ü¹éÁú ĨÀÇ ÀÌ¿ë »ç·Ê¸¦ È®´ëÇß½À´Ï´Ù.

¾Ï, ½ÉÇ÷°ü°è Áúȯ, ½Å°æ°è Áúȯ µî ¸¸¼ºÁúȯÀÇ È®»êÀ¸·Î Áúº´ Áø´Ü ¹× Ä¡·á¸¦ À§ÇÑ Ã·´Ü Åø¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´Ü¹éÁú ĨÀº Áúº´¿¡ ƯȭµÈ ´Ü¹éÁú ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°ÇÏ¿© Á¶±â ¹ß°ß ¹× ¸ÂÃã Ä¡·á Àü·«À» Áö¿øÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 10¿ù Sengenics Corporation LLC´Â Áúº´ °ü·Ã ÀÚ°¡Ç×ü °ËÃâÀ» À§ÇÑ Á¤¹Ð ´Ü¹éÁú ¸¶ÀÌÅ©·Î¾î·¹ÀÌ Ç÷§ÆûÀÎ i-Ome DiscoveryÀÇ Ãâ½Ã¸¦ ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. SengenicsÀÇ Æ¯Çã ±â¼úÀÎ KREX¸¦ Ȱ¿ëÇÏ¿© ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, ½Å°æÅðÇ༺ Áúȯ°ú °ü·ÃµÈ 1,800°³ ÀÌ»óÀÇ ÀÚ°¡Ç׿øÀ» Á¤È®ÇÏ°Ô °ËÃâÇÒ ¼ö ÀÖÀ¸¸ç, Áúº´¿¡¼­ ´Ü¹éÁú°ú ¸é¿ªÃ¼°èÀÇ »óÈ£ÀÛ¿ëÀ» ÀÌÇØÇÏ´Â Çмú¿¬±¸ÆÀ°ú ÀÓ»ó ¿¬±¸ÆÀÀ» Áö¿øÇÕ´Ï´Ù. ÀÌ´Â ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª ´Ü¹éÁú Ĩ ±â¼úÀº °í°¡ÀÇ Àåºñ, ½Ã¾à ¹× Àü¹® Áö½ÄÀ» ÇÊ¿ä·Î ÇÏ´Â °æ¿ì°¡ ¸¹¾Æ ÀϺΠ¿¬±¸ÀÚ ¹× ¿¬±¸¼Ò¿¡ ÁøÀÔÀ庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ´Ü¹éÁú Ĩ ºÐ¼®ÀÇ ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æÀ̳ª ´ë±Ô¸ð ¿¬±¸¿¡¼­ÀÇ »ç¿ëÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´Ü¹éÁú Ĩ ±â¼úÀº ´Ü¹éÁú °íÁ¤È­, ºÐ¼® °³¹ß ¹× µ¥ÀÌÅÍ ºÐ¼®¿¡ º¹ÀâÇÑ ÀýÂ÷°¡ ÇÊ¿äÇÕ´Ï´Ù. µû¶ó¼­ ¼­·Î ´Ù¸¥ Ç÷§Æû°ú ½ÇÇè½Ç °£ÀÇ Ç¥ÁØÈ­ ¹× ÀçÇö¼ºÀÌ ¾î·Á¿ö ´Ü¹éÁú ĨÀÇ º¸±ÞÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´Ü¹éÁúĨ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • À¯Çüº°·Î´Â ºÐ¼®¿ë ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ºÐ¾ß°¡ 2023³â 54.86%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇÏ¸ç ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºÐ¼®¿ë ¸¶ÀÌÅ©·Î¾î·¹À̸¦ »ç¿ëÇÏ¸é ´ÙÁßÈ­¸¦ ÅëÇØ ÇϳªÀÇ »ùÇÿ¡¼­ ¿©·¯ ´Ü¹éÁúÀ» µ¿½Ã¿¡ °ËÃâÇϰí Á¤·®È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ¿¹Ãø ±â°£ Áß ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
  • ¿ëµµº°·Î´Â Ç×ü ºÐ¾ß°¡ 2023³â 56.52%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ÀÌ´Â ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö¿¡ ³Î¸® »ç¿ëµÇ¸é¼­ Ç×ü ±â¹Ý ´Ü¹éÁú Ĩ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¹Ý¸é, ÀÓ»ó Áø´Ü ºÎ¹®Àº ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â »ý¹°ÇÐ, »ýÈ­ÇÐ, ¾à¸®ÇÐ, ÀÇÇÐ µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ ´Ü¹éÁú ĨÀÌ ´Ü¹éÁú ºÐ¼®, ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö, ¾à¹° °³¹ß, Áúº´ Áø´ÜÀ» ½ÇÇöÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, Çмú ¹× ¿¬±¸±â°ü ºÎ¹®ÀÌ 2023³â 51.56%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì´Â ¾Ï ¹ßº´·ü Áõ°¡, ÁÂ½Ä »ýȰ½À°ü, ºñ¸¸ Àα¸ Áõ°¡·Î ÀÎÇØ 2023³â 48.17%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • ¸ð½ÃÀå Àü¸Á
    • °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ¾÷°è ºÐ¼® Åø
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå À¯Çü ºñÁî´Ï½º ºÐ¼®

  • À¯Çü ºÎ¹® ´ë½Ãº¸µå
  • ´Ü¹éÁú Ĩ ½ÃÀåÀÇ À¯Çü º¯µ¿ ºÐ¼®
  • ´Ü¹éÁú Ĩ ½ÃÀå ±Ô¸ð¡¤µ¿Ç⠺м®, À¯Çüº°, 2018-2030³â
  • ºÐ¼®¿ë ¸¶ÀÌÅ©·Î¾î·¹ÀÌ
  • ±â´É¼º ´Ü¹éÁú ¸¶ÀÌÅ©·Î¾î·¹ÀÌ
  • ¿ª»ó ´Ü¹éÁú ¸¶ÀÌÅ©·Î¾î·¹ÀÌ

Á¦5Àå ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
  • ´Ü¹éÁú Ĩ ½ÃÀåÀÇ ¿ëµµ º¯µ¿ ºÐ¼®
  • ´Ü¹éÁú Ĩ ½ÃÀå ±Ô¸ð¡¤µ¿Ç⠺м®, ¿ëµµº°, 2018-2030³â
  • Ç×ü Ư¼º Æò°¡
  • ÀÓ»ó Áø´Ü
  • ÇÁ·ÎÅ׿À¹Í½º
  • ±âŸ

Á¦6Àå ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ÃÖÁ¾ ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
  • ´Ü¹éÁú Ĩ ½ÃÀåÀÇ ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ´Ü¹éÁú Ĩ ½ÃÀå ±Ô¸ð¡¤µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
  • º´¿ø¡¤Å¬¸®´Ð
  • Áø´Ü ¿¬±¸¼Ò
  • Çмú¡¤¿¬±¸±â°ü
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷

Á¦7Àå Áö¿ªÀÇ ºñÁî´Ï½º ºÐ¼®

  • Áö¿ªÀÇ ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø¡¤µ¿Ç⠺м®, 2023³â°ú 2030³â
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ½ÃÀå ÇöȲ ºÐ¼®, 2023³â
  • ±â¾÷ °³¿ä/»óÀå±â¾÷
    • Agilent Technologies
    • PerkinElmer
    • Bio-Rad Laboratories
    • Thermo Fisher Scientific
    • Sigma-Aldrich Corporation
    • Illumina
    • Shimadzu Corporation
    • Roche Diagnostics
    • RayBiotech
    • Danaher
KSA 24.05.20

Protein Chip Market Growth & Trends:

The global protein chip market size is anticipated to reach USD 3.36 billion by 2030 and is projected to grow at a CAGR of 6.88% from 2024 to 2030, according to a new report by Grand View Research, Inc. This is attributed to the continuous advancements in proteomics research, increasing drug discovery and developments, and ongoing technological advancements are anticipated to increase the demand for protein chips over the forecast period.

The COVID-19 pandemic has had a positive impact on the global market. The COVID-19 outbreak has brought to the forefront the significance of cutting-edge technologies such as protein chips in tackling worldwide health issues. This has spurred innovation, amplified investments, and broadened the use cases of protein chips in disease investigation, diagnostics, and tailored healthcare.

The growing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders fuels the demand for advanced tools for disease diagnosis and treatment. Protein chips enable the identification of disease-specific protein biomarkers, aiding in early detection and personalized treatment strategies. For instance, in October 2023, Sengenics Corporation LLC announced the launch of i-Ome Discovery, a precise protein microarray platform for detecting disease-related autoantibodies. It aids academic and clinical research teams in understanding protein-immune system interactions in diseases. Utilizing Sengenics' patented KREX technology, it offers accurate detection of over 1,800 autoantigens relevant to cancer, autoimmune, and neurodegenerative disorders. Thus, anticipated to propel the demand for market growth over the forecast period.

However, protein chip technologies often require expensive equipment, reagents, and specialized expertise, which can pose a barrier to entry for some researchers and laboratories. The high cost of protein chip assays may limit their use in resource-constrained settings or for large-scale studies. Moreover, protein chip technologies involve complex procedures for protein immobilization, assay development, and data analysis. Thus, standardization and reproducibility across different platforms and laboratories is challenging, thus limiting the widespread adoption of protein chips. Thereby anticipated to hamper the market growth.

Protein Chip Market Report Highlights:

  • Based on type, the analytical microarray segment led the market with the largest revenue share of 54.86% in 2023 and is expected to grow at the fastest CAGR over the forecast period. The use of analytical microarrays enables multiplexing, which allows simultaneous detection and quantification of multiple proteins in a single sample. Thereby boosting the segmental growth over the forecast period
  • Based on application, the antibody segment held the market with the largest revenue share of 56.52% in 2023. This is attributed to the increasing demand of antibody-based protein chips due to their wide use in biomarker discovery efforts. On the other hand, the clinical diagnostics segment is expected to grow at the fastest CAGR over the forecast period
  • Based on end-use, the academic & research institutes segment led the market with the largest revenue share of 51.56% in 2023, as a wide range of studies in fields such as biology, biochemistry, pharmacology, and medicine, where protein chips play a crucial role in enabling protein analysis, biomarker discovery, drug development, and disease diagnostics
  • North America dominated the market with the revenue share of 48.17% in 2023, due to growing cancer incidence, sedentary lifestyle, and rising prevalence of obese population. On the other hand, Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Type Segment
    • 1.1.2. Application Segment
    • 1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Primary Research
  • 1.6. Information or Data Analysis:
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations
  • 1.11. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Advancements in proteomics research
      • 3.2.1.2. Rising incidence of chronic diseases
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost
      • 3.2.2.2. Data analysis complexity
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. Protein Chip Market Type Movement Analysis
  • 4.3. Protein Chip Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Analytical Microarrays
    • 4.4.1. Analytical microarrays market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Functional Protein Microarrays
    • 4.5.1. Functional protein microarrays market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6. Reverse Phase Protein Microarrays
    • 4.6.1. Reverse phase protein microarrays market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Application Group Business Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. Protein Chip Market Application Movement Analysis
  • 5.3. Protein Chip Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Antibody Characterization
    • 5.4.1. Antibody characterization market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Clinical Diagnostics
    • 5.5.1. Clinical diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Proteomics
    • 5.6.1. Proteomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

  • 6.1. End-use Segment Dashboard
  • 6.2. Protein Chip Market End Use Movement Analysis
  • 6.3. Protein Chip Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals & Clinics
    • 6.4.1. Hospitals & clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Diagnostic Laboratories
    • 6.5.1. Diagnostic laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Academic & Research Institutes
    • 6.6.1. Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Pharmaceutical & Biotechnology Companies
    • 6.7.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis by Type, Application, End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecast and Trend Analysis, 2023 & 2030
  • 7.3. North America
    • 7.3.1. North America Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada Protein Chip Market, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Italy Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Spain Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Denmark Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Framework
      • 7.4.8.4. Sweden Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Framework
      • 7.4.9.4. Norway Protein Chip Market, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Japan Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. China Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. India Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Australia Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Thailand Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. South Korea Protein Chip Market, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Brazil Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.6.3. Mexico
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Mexico Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.6.4. Argentina
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Argentina Protein Chip Market, 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. South Africa Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Saudi Arabia Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. UAE Protein Chip Market, 2018 - 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Kuwait Protein Chip Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Agilent Technologies
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. PerkinElmer
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Bio-Rad Laboratories
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Thermo Fisher Scientific
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Sigma-Aldrich Corporation
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Illumina
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Shimadzu Corporation
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Roche Diagnostics
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. RayBiotech
      • 8.4.9.1. Overview
      • 8.4.9.2. Product Benchmarking
      • 8.4.9.3. Strategic Initiatives
    • 8.4.10. Danaher
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦